|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 690.26 USD | +2.00% |
|
+2.39% | -12.04% |
| 06:35pm | Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating | MT |
| 16/07 | Merck gets US FDA nod for first-in-its-class oral cholesterol drug | RE |
| Market Cap | 6.88TCr 6.03TCr 5.58TCr 5.13TCr 9.68TCr 6,63900Cr 9.83TCr 67TCr 26TCr 3,24800Cr 26TCr 25TCr 11,19100Cr | P/E 2026 * |
17.8x | P/E 2027 * | 14.3x |
|---|---|---|---|---|---|
| Enterprise Value | 6.1TCr 5.35TCr 4.94TCr 4.55TCr 8.58TCr 5,88500Cr 8.72TCr 59TCr 23TCr 2,87900Cr 23TCr 22TCr 9,92000Cr | EV / Sales 2026 * |
3.84x | EV / Sales 2027 * | 3.31x |
| Free-Float |
72.33% | Yield 2026 * |
0.58% | Yield 2027 * | 0.66% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +0.01% | ||
| 1 week | +2.39% | ||
| Current month | +8.88% | ||
| 1 month | +10.84% | ||
| 3 months | -9.41% | ||
| 6 months | -7.48% | ||
| Current year | -12.04% |
| 1 week | 648.66 |  | 691.13 |
| 1 month | 594.9 | | 691.13 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/07/26 | Sell | Director | -200 | 0.0002% | ||
| 01/05/26 | Sell | Director | -100 | 0.0001% | ||
| 01/04/26 | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.00% | +2.39% | +24.45% | -6.10% | 6.88TCr | |
| -0.54% | +0.38% | +36.12% | +192.81% | 5.21TCr | |
| -3.65% | +34.50% | +34.50% | +34.50% | 4.35TCr | |
| -0.58% | -0.23% | -52.36% | -53.82% | 4.12TCr | |
| -2.10% | -2.94% | +65.37% | -26.15% | 3.04TCr | |
| -3.28% | -8.47% | +98.05% | -50.84% | 2.45TCr | |
| +2.14% | +1.14% | +71.46% | +80.49% | 2.34TCr | |
| +3.99% | +3.12% | +3.87% | +200.81% | 1.98TCr | |
| +0.26% | +0.39% | +72.12% | +126.52% | 1.66TCr | |
| +0.92% | -2.11% | +77.18% | +135.79% | 1.6TCr | |
| Average | -0.39% | -1.40% | +43.08% | +63.40% | 3.36TCr | |
| Weighted average by Cap. | -0.66% | -0.66% | +34.12% | +50.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.59TCr 1.39TCr 1.29TCr 1.18TCr 2.23TCr 1,53100Cr 2.27TCr 15TCr 6.03TCr 75TCr 5.96TCr 5.83TCr 2,58100Cr | 1.76TCr 1.55TCr 1.43TCr 1.31TCr 2.48TCr 1,70200Cr 2.52TCr 17TCr 6.7TCr 83TCr 6.63TCr 6.48TCr 2,86800Cr |
| Net income | 398.92Cr 349.66Cr 323.2Cr 297.25Cr 560.86Cr 38TCr 569.86Cr 3.86TCr 1.51TCr 19TCr 1.5TCr 1.47TCr 65TCr | 502.61Cr 440.54Cr 407.21Cr 374.52Cr 706.65Cr 48TCr 717.98Cr 4.87TCr 1.91TCr 24TCr 1.89TCr 1.85TCr 82TCr |
| Net Debt | -782.28Cr -685.67Cr -633.79Cr -582.91Cr -1.1TCr -75TCr -1.12TCr -7.58TCr -2.97TCr -37TCr -2.94TCr -2.87TCr -1,27200Cr | -1.05TCr -921.46Cr -851.75Cr -783.36Cr -1.48TCr -1,01400Cr -1.5TCr -10TCr -3.99TCr -50TCr -3.95TCr -3.86TCr -1,70900Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | $673.79 | -0.43% | 3,37,654 |
| 17/26/17 | $676.69 | -0.33% | 6,48,400 |
| 16/26/16 | $678.94 | +2.18% | 7,30,245 |
| 15/26/15 | $664.45 | +1.27% | 5,55,419 |
| 14/26/14 | $656.12 | -1.05% | 4,77,991 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
